Other

2027

Biogen 2027 remained flat by 0.0% to $485.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 13.4%, from $560.00M to $485.00M. Over 3 years (FY 2020 to FY 2023), 2027 shows an upward trend with a 18.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionOther
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ1 2021
Last reportedQ1 2026

How to read this metric

Lower projected expenses indicate a reduction in the drag on future net income as assets become fully amortized.

Detailed definition

This represents the projected amortization expense for finite-lived intangible assets for the year 2027. These assets ty...

Peer comparison

Standard disclosure for banks with significant historical acquisition activity.

Metric ID: other_finite_lived_intangible_assets_amortization_expens_a31c97

Historical Data

18 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$215.00M$255.00M$255.00M$210.00M$210.00M$215.00M$215.00M$195.00M$200.00M$325.00M$345.00M$565.00M$565.00M$510.00M$560.00M$565.00M$485.00M$485.00M
QoQ Change+18.6%+0.0%-17.6%+0.0%+2.4%+0.0%-9.3%+2.6%+62.5%+6.2%+63.8%+0.0%-9.7%+9.8%+0.9%-14.2%+0.0%
YoY Change-2.3%-15.7%-15.7%-7.1%-4.8%+51.2%+60.5%+189.7%+182.5%+56.9%-0.9%+0.0%-4.9%-13.4%
Range$195.00M$565.00M
CAGR+21.1%
Avg YoY Growth+34.0%
Median YoY Growth-1.6%

Frequently Asked Questions

What is Biogen's 2027?
Biogen (BIIB) reported 2027 of $485.00M in Q1 2026.
How has Biogen's 2027 changed year-over-year?
Biogen's 2027 decreased by 13.4% year-over-year, from $560.00M to $485.00M.
What is the long-term trend for Biogen's 2027?
Over 3 years (2020 to 2023), Biogen's 2027 has grown at a 18.9% compound annual growth rate (CAGR), from $205.00M to $345.00M.
What does 2027 mean?
The expected non-cash expense for acquired intangible assets in the year 2027.